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INTRODUCTION
The carcinoembryonic antigen (CEA), first described by
Gold and Freedman in 1965, is a highly glycosylated cell
surface glycoprotein with a molecular weight of 180,000,
which is believed to be an oncofetal protein specific for the
colon (1). The potential use of a circulating tumor marker
includes screening the populations at risk of developing a
tumor, making an unequivocal diagnosis of the presence of
a tumor, determining the prognosis, assessing the therapeu-
tic efficacy, and detecting residual or recurrent cancer. Cur-
rently, the performance of the available tumor markers as
screening tests for diagnosing a malignancy in high risk
individuals is inadequate because of the reduced sensitivity
and occasional false-positive results (1-3). However, several
studies have suggested that measuring the CEA in the body
fluid bathing primary or metastatic tumors may be more
useful than the serum value (4-14). The aim of this study
was to determine the diagnostic role of the bile CEA levels
in patients with bile duct cancer.
MATERIALS AND METHODS
The study included 132 patients with biliary tract dis-
eases or pancreatic head cancer with a bile duct invasion from
November 2001 to May 2003, who had undergone an endo-
scopic biliary drainage or a percutaneous transhepatic bil-
iary drainage as a result of a biliary obstruction with/with-
out cholangitis. The exclusion criteria were an associated
other site tumor that may have influenced the bile CEA lev-
els, some biliary tract malignancies such as gallbladder or
ampulla of Vater cancer, pancreatic body or tail cancer, and
bile obtained directly from the gallbladder. Serum samples
were taken from all the patients immediately before the bil-
iary drainage procedures and bile samples were obtained from
the drainage catheter on the next day of the biliary drainage
procedures in order to exclude dilution effects of the previous
injected dyes. The bile CEA levels were determined with a
two-site sandwich immunoassay using a direct chemilumi-
nometric technique (ADVIA Centaur CEA assay, Bayer, East
Walpole, MA, U.S.A.).
The patients’ age ranged from 25 to 91 yr (mean 63.0±
13.2), and the male to female ratio was 77:55. All the patients
were divided into 3 groups: the bile duct cancer (n=32), the
pancreatic cancer (n=16), and the benign biliary diseases
(n=84) groups (Table 1). The benign biliary diseases con-
sisted of 62 common bile duct stones, 6 intrahepatic duct
stones, 10 both intra and extrahepatic duct stones, 6 benign
bile duct strictures with/without stones. Both bile duct and
pancreatic cancer were diagnosed by the radiographic stud-
ies or pathological findings of the biopsy specimens and/or
by the operative findings with/without pathological exami-
nation of resected tumors. Statistical analysis was performed
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It is known that the fluids bathing tumors might contain a higher level of the carcino-
embryonic antigen (CEA) than those found in the blood. Therefore, we evaluated
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bile duct cancer (n=32), pancreatic cancer (n=16), and benign biliary diseases
(n=84) groups. Bile samples were obtained on the next day of the biliary drainage
procedures. The mean bile CEA level in those with bile duct cancer (120.6±156.9
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iary diseases (32.0±28.5 ng/mL, 29.3±56.3 ng/mL). Using the level of 20 ng/mL,
the sensitivity and specificity of bile CEA in the diagnosis of bile duct cancer from
benign biliary diseases were 65.6% and 66.7%, respectively. Both the bile CEA
and total bilirubin level were found to be an independent factor linked to bile duct
cancer. This study result suggests that bile CEA level is a useful supplementary test
for diagnosing bile duct cancer.
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by a one-way analysis of variance (ANOVA) to analyze the
differences in the variables including the bile CEA level among
the groups, and by logistic regression to evaluate the diag-
nostic value of the bile CEA level. The results are expressed
as a mean±standard deviation of the mean. A pvalue <0.05
was considered significant. Statistical analysis was done using
the SPSS/PC+ version 9.0 software.
RESULTS
The distribution of the bile CEA levels among the groups
is shown in Fig. 1. The mean bile CEA in the bile duct can-
cer group was 120.6±156.9 ng/mL, 32.0±28.5 ng/mL in
the pancreatic cancer group, and 29.3±56.3 ng/mL in the
benign biliary diseases group. The mean bile CEA level in
the bile duct cancer patients was significantly higher than
in the pancreatic cancer and benign biliary diseases patients
(p<0.05). On the other hand, the mean bile CEA level in the
pancreatic cancer patients was not statistically different from
that in the benign biliary diseases patients. As the normal
value of bile CEA was not known, we had to determine the
receiver operating characteristic (ROC) curves. Therefore, a
value of 20 ng/mL was chosen to significantly improve the
specificity, without reducing the sensitivity. Using a cut-off
level of 20 ng/mL, the sensitivity and specificity of the bile
CEA in detecting bile duct cancer was 65.6% and 66.7%,
respectively. In addition to the bile CEA levels, the total
bilirubin and alkaline phosphatase level were also found to
be significantly different among the groups (Table 1). To
determine whether or not the bile CEA levels were related
to a biliary obstruction, the bile CEA levels were compared
with a liver function test. The bile CEA did not correlate
with either the bilirubin or alkaline phosphatase levels (Table
2). Among the variables, the bile CEA, total bilirubin, alka-
line phosphatase, and  GT levels directly correlated with a
malignancy in biliary tract diseases including bile duct can-
cer and benign biliary diseases. In particular, both the bile
CEA and total bilirubin level were found to be an indepen-
dent factor linked to bile duct cancer (p<0.05).
DISCUSSION
CEA is a 180,000 Da glycoprotein that is often found in
patients with malignant tumors of the digestive system (1,
2). This antigen has been detected in various body fluids
such as the gastrointestinal and pancreatobiliary juice (4-14).
Several studies have described the diagnostic utility of the
increased CEA levels in the body fluids in primary malignant
tumors arising from the stomach, colon, biliary tract, and
pancreas (4-11). In particular, some attempts have been made
to analyze the bile juice for a measurement of the CEA con-
tent to predict the presence of bile duct cancer (7-11). In
addition to a primary malignant tumor, the relationships
*Values of data are the mean±SD except for male sex ratio and Clonor-
chis sinensis infection rate. 
� Significantly different at p<0.05 between
bile duct cancer and benign biliary diseases. CS, Clonorchis sinensis
infection rate.
Bile duct  Pancreatic Benign biliary
cancer cancer diseases
No. 32 16 84
Age (yr) 62.8±11.8 67.8±10.5 62.1±14.1
Male (%) 69 69 52
WBC (× 10
3/ L) 9.0±3.5 8.7±4.5 8.6±4.1
Bile CEA (ng/mL)
� 120.6±156.9 32.0±28.5 29.3±56.3
Bilirubin (mg/dL)
� 7.7±5.8 7.1±5.9 3.0±5.0
AST (IU/L) 116.6±125.6 166.9±160.2 147.6±194.7
ALT (IU/L) 152.5±157.5 229.1±194.3 156.9±170.6
ALP (IU/L)
� 375.5±266.0 421.5±226.3 237.4±196.1
GT (IU/L) 576.2±512.2 605.3±408.2 394.8±369.1
CS (%) 44 23 29
Table 1. Comparative data* among the groups
*p<0.05. 
� p<0.01.
bCEA, biliary CEA; BIL, total bilirubin; ALP, alkaline phosphatase.
bCEA BIL AST ALT ALP GT
bCEA 1
BIL .058 1
AST .034 -.013 1
ALT -.004 .067 .825
� 1
ALP .060 .338
� .162 .194* 1
GT .097 .184* .222* .349
� .647
� 1
Table 2. Correlation between biliary CEA and liver function test
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Fig.1 Distribution of the bile CEA levels according to the groups.
The level of CEA in patients with bile duct cancer is significantly
different in comparison with those in patients with pancreatic can-
cer and benign biliary diseases. Bars are expressed as mean.Bile CEA in Diagnosing Bile Duct Cancer 857
between the bile CEA levels in the gallbladder or bile duct
and a colorectal liver metastasis have been also reported (12-
14). These attempts to determine the CEA level in the body
fluids may be attributed to the notion that the fluids bathing
the tumors in the primary or metastatic sites might contain
higher CEA levels than those found in the blood pool. Unfor-
tunately, several reports have shown nonspecific elevations
of the bile CEA levels in benign biliary diseases patients, e.g.
choledocholithiasis (8-11, 15).
In contrary to the bile CEA levels, the serum CEA level
may be controlled by several factors, including the produc-
tion of CEA by cancer cells, the release from the tumor direct-
ly into the blood stream and its metabolic degradation in
the liver (16, 17). However, the body fluids including bile,
cystic fluids, and gastrointestinal juice, are in close contact
with or contain the tumors, so they have a large quantity of
CEA discharged from the tumor itself. Moreover, this con-
siderable portion is not exposed to the degradation process
in the liver (18). In addition, the elevated CEA levels in body
fluids become rapidly detectable because their volume is much
smaller than the blood volume (19). Therefore, a CEA assay
of the fluids bathing a tumor may be a more reliable system
as an aid in diagnosis than that in the serum. In this respect,
this study focused on whether or not the bile CEA level would
be a useful tool for diagnosing bile duct cancer. In particu-
lar, as the bile obtained from the bile duct is directly in con-
tact with bile duct cancer and is not affected by either the
gallbladder function or the cystic duct patency (7). Therefore,
it is expected that a hepatic bile CEA assessment would be
more useful in diagnosing bile duct cancer, compared to gall-
bladder or pancreatic cancer. These results showed that the
bile CEA level in bile duct cancer patients was significantly
higher than that in benign biliary diseases patients. Further-
more, logistic regression analysis of the variables showed that
the bile CEA level in addition to the total bilirubin level are
independent variables linked to bile duct cancer. It is sug-
gested that the bile CEA level may to some extent be a use-
ful supplementary tool in distinguishing bile duct cancer
from benign biliary diseases, particularly in an equivocal sit-
uation, which is unjustly suspected of bile duct cancer. How-
ever, the bile CEA level in pancreatic cancer patients was not
only lower than that in bile duct cancer patients, but there
was also no difference from that in the benign biliary diseases
patients. This may be partly caused by the anatomical sepa-
ration between the common bile duct and the pancreatic
tumor despite the biliary obstruction by the tumor. 
As mentioned above, several studies have indicated that
nonspecific elevations of the bile CEA levels were observed in
patients with benign biliary diseases (8-11, 15). This phe-
nomenon may be explained by the fact that human bile con-
tains several CEA related substances such as biliary glycopro-
tein 1, a nonspecific cross-reacting antigen that can poten-
tially cross-react with CEA (10). Hence, the values for the
CEA levels in the bile may be influenced by the presence of
CEA related substances. To overcome this problem, a recent
study performed immunochemical analysis for a specific CEA
investigation, and observed that CEA was found only in those
patients with bile duct cancer whereas only CEA related-
substances were found in benign biliary diseases patients. This
suggests that the Western blot analysis of bile CEA can dif-
ferentiate CEA from CEA related substances and be helpful
for detecting the presence of a tumor (10). Unfortunately,
this study did not perform the Western blot analysis of bile
CEA. Nevertheless, it is obvious that in some bile duct can-
cers, the bile CEA level will be significantly higher than in
benign biliary diseases patients.
In conclusion, bile CEA appears to have a limited use in
screening for bile duct cancer because of its low sensitivity and
specificity. However, in some situations, particularly when the
diagnosis remains obscure, the bile CEA level may be applied
as a useful supplementary test in making a distinction between
malignant and benign biliary diseases.
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